JP2022505041A5 - - Google Patents

Info

Publication number
JP2022505041A5
JP2022505041A5 JP2021520936A JP2021520936A JP2022505041A5 JP 2022505041 A5 JP2022505041 A5 JP 2022505041A5 JP 2021520936 A JP2021520936 A JP 2021520936A JP 2021520936 A JP2021520936 A JP 2021520936A JP 2022505041 A5 JP2022505041 A5 JP 2022505041A5
Authority
JP
Japan
Prior art keywords
adc
atr inhibitor
pharmaceutically acceptable
dna
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021520936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/077784 external-priority patent/WO2020078905A1/en
Publication of JP2022505041A publication Critical patent/JP2022505041A/ja
Publication of JP2022505041A5 publication Critical patent/JP2022505041A5/ja
Pending legal-status Critical Current

Links

JP2021520936A 2018-10-15 2019-10-14 Dnaアルキル化剤及びatr阻害剤を使用する併用療法 Pending JP2022505041A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18200527 2018-10-15
EP18200527.2 2018-10-15
PCT/EP2019/077784 WO2020078905A1 (en) 2018-10-15 2019-10-14 Combination therapy utilizing dna alkylating agents and atr inhibitors

Publications (2)

Publication Number Publication Date
JP2022505041A JP2022505041A (ja) 2022-01-14
JP2022505041A5 true JP2022505041A5 (cg-RX-API-DMAC7.html) 2022-10-21

Family

ID=63862065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520936A Pending JP2022505041A (ja) 2018-10-15 2019-10-14 Dnaアルキル化剤及びatr阻害剤を使用する併用療法

Country Status (8)

Country Link
US (1) US12616750B2 (cg-RX-API-DMAC7.html)
EP (1) EP3866785A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022505041A (cg-RX-API-DMAC7.html)
CN (1) CN113164447A (cg-RX-API-DMAC7.html)
AU (2) AU2019360608A1 (cg-RX-API-DMAC7.html)
CA (1) CA3116234A1 (cg-RX-API-DMAC7.html)
IL (1) IL282312A (cg-RX-API-DMAC7.html)
WO (1) WO2020078905A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
CA3183867C (en) * 2020-06-24 2025-06-10 Astrazeneca Uk Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND AN ATR INHIBITOR
TW202320857A (zh) * 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023010021A1 (en) 2021-07-27 2023-02-02 Xencor, Inc. Il-18-fc fusion proteins
IL317037A (en) * 2022-05-18 2025-01-01 Systimmune Inc Ligand-drug conjugate and its uses
KR20250037789A (ko) * 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
NO3056203T3 (cg-RX-API-DMAC7.html) 2010-04-21 2018-05-12
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143423A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼ阻害剤として有用な化合物
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
JP2013529643A (ja) 2010-06-23 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピロロピラジン誘導体
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (cg-RX-API-DMAC7.html) 2011-09-30 2015-08-21 Vertex Pharma
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
EP3077393A1 (en) 2013-12-06 2016-10-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2015104373A2 (en) 2014-01-10 2015-07-16 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in treatment of endometrial cancer
DK2948184T3 (en) * 2014-01-10 2016-06-27 Synthon Biopharmaceuticals Bv Duocarmycin-ADCs with improved in vivo antitumor activity
NO2714752T3 (cg-RX-API-DMAC7.html) * 2014-05-08 2018-04-21
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Similar Documents

Publication Publication Date Title
Sun et al. Multiple roles of autophagy in the sorafenib resistance of hepatocellular carcinoma
JP2019517549A5 (cg-RX-API-DMAC7.html)
EP2785349B1 (en) Combination treatment of cancer
JP2008507536A5 (cg-RX-API-DMAC7.html)
JP2018502120A5 (cg-RX-API-DMAC7.html)
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
JP2022511394A5 (cg-RX-API-DMAC7.html)
JP2020521797A5 (cg-RX-API-DMAC7.html)
JP2005532332A5 (cg-RX-API-DMAC7.html)
JP2016536286A5 (cg-RX-API-DMAC7.html)
JP2014515373A5 (cg-RX-API-DMAC7.html)
JP2017503820A5 (cg-RX-API-DMAC7.html)
MX387397B (es) Régimen de dosificación para el tratamiento de tumores sólidos.
JP2022019973A5 (cg-RX-API-DMAC7.html)
JP2022502399A5 (cg-RX-API-DMAC7.html)
JP2016527202A5 (cg-RX-API-DMAC7.html)
JP2019506392A5 (cg-RX-API-DMAC7.html)
JPWO2020250915A5 (cg-RX-API-DMAC7.html)
TW201313228A (zh) N-羥基-4-{2-[3-(n,n-二甲基胺基甲基)苯並呋喃-2-基羰基胺基]乙氧基}苯甲醯胺之新穎投藥法
JP2021500409A5 (cg-RX-API-DMAC7.html)
JP2019534251A5 (cg-RX-API-DMAC7.html)
JP2021511344A5 (cg-RX-API-DMAC7.html)
JP2021505669A5 (cg-RX-API-DMAC7.html)
JP2014510047A5 (cg-RX-API-DMAC7.html)
JP2018511642A5 (cg-RX-API-DMAC7.html)